Literature DB >> 30456537

A Practical Guide to Curing Onychomycosis: How to Maximize Cure at the Patient, Organism, Treatment, and Environmental Level.

Aditya K Gupta1,2, Sarah G Versteeg3, Neil H Shear4, Vincent Piguet4,5, Antonella Tosti6, Bianca Maria Piraccini7.   

Abstract

Onychomycosis is a fungal nail infection caused by dermatophytes, non-dermatophyte molds, and yeasts. Treatment of this infection can be difficult, with relapse likely to occur within 2.5 years of cure. The objective of this article is to review factors that can impact cure and to suggest practical techniques that physicians can use to maximize cure rates. Co-morbidities, as well as disease severity and duration, are among the many patient factors that could influence the efficacy of antifungal therapies. Furthermore, organism, treatment, and environmental factors that may hinder cure include point mutations, biofilms, affinity for non-target enzymes, and exposure to fungal reservoirs. To address patient-related factors, physicians are encouraged to conduct confirmatory testing and treat co-morbidities such as tinea pedis early and completely. To combat organism-focused factors, it is recommended that disruption of biofilms is considered, and drugs with multiple routes of delivery and unique mechanisms of action are prescribed when traditional agents are not effective. Extending follow-up periods, using combination treatments, and considering pulse regimens may also be of benefit. Through these practical techniques, physicians can maximize cure and limit the risk of relapse and re-infection.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30456537     DOI: 10.1007/s40257-018-0403-4

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  9 in total

Review 1.  A Paradigm Shift in the Treatment and Management of Onychomycosis.

Authors:  Aditya K Gupta; Maanasa Venkataraman; Helen J Renaud; Richard Summerbell; Neil H Shear; Vincent Piguet
Journal:  Skin Appendage Disord       Date:  2021-05-11

2.  Cold Atmospheric Pressure Plasma Jet Reduces Trichophyton rubrum Adherence and Infection Capacity.

Authors:  Aline Chiodi Borges; Thalita Mayumi Castaldelli Nishime; Sabrina de Moura Rovetta; Gabriela de Morais Gouvêa Lima; Konstantin Georgiev Kostov; Gilmar Patrocínio Thim; Beatriz Rossi Canuto de Menezes; João Paulo Barros Machado; Cristiane Yumi Koga-Ito
Journal:  Mycopathologia       Date:  2019-08-30       Impact factor: 2.574

3.  A Week of Oral Terbinafine Pulse Regimen Every Three Months to Treat all Dermatophyte Onychomycosis.

Authors:  Anarosa B Sprenger; Katia Sheylla Malta Purim; Flávia Sprenger; Flávio Queiroz-Telles
Journal:  J Fungi (Basel)       Date:  2019-09-04

Review 4.  Recent advances in therapies for onychomycosis and its management.

Authors:  Aditya K Gupta; Nadia Stec
Journal:  F1000Res       Date:  2019-06-25

5.  Human Nails Permeation of an Antifungal Candidate Hydroalcoholic Extract from the Plant Sapindus saponaria L. Rich in Saponins.

Authors:  Vanessa Mendes; Flávia Franco Veiga; Lidiane Vizioli de Castro-Hoshino; Francielle Sato; Mauro Luciano Baesso; Beatriz Vesco; Elton Cruz; Izabel Cristina Piloto Ferreira; Melyssa Negri; Terezinha Inez Estivalet Svidzinski
Journal:  Molecules       Date:  2021-01-05       Impact factor: 4.411

6.  Cold atmospheric pressure plasma (CAPP) as a new alternative treatment method for onychomycosis caused by Trichophyton verrucosum: in vitro studies.

Authors:  Sebastian Gnat; Dominik Łagowski; Mariusz Dyląg; Jessica Zielinski; Marek Studziński; Aneta Nowakiewicz
Journal:  Infection       Date:  2021-09-09       Impact factor: 3.553

7.  Combination of a triple wavelength (650 nm, 810 nm, and 915 nm) class IV laser system and local mechanical abrasion in the treatment of chronic toenail onychomycosis: an uncontrolled prospective pilot study.

Authors:  Aurelija E Aukstikalnyte; Eva Cibien; Pamela De Demo; Klaus Eisendle
Journal:  Int J Dermatol       Date:  2021-08-27       Impact factor: 3.204

8.  NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile.

Authors:  Derry K Mercer; Jennifer C Robertson; Lorna Miller; Colin S Stewart; Deborah A O'Neil
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

9.  The Success of Topical Treatment of Onychomycosis Seems to Be Influenced by Fungal Features.

Authors:  Vanessa Vasconcellos-Pontello; Flávia Franco Veiga; Marina Cristina Gadelha; Marielen Ribeiro; Melyssa Negri; Terezinha Inez Estivalet Svidzinski
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-09       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.